A proposed staging system and stage-specific interventions for familial adenomatous polyposis.

ABSTRACT:

Background and aims

It is not possible to accurately count adenomas in many patients with familial adenomatous polyposis (FAP). Nevertheless, polyp counts are critical in evaluating each patient's response to interventions. However, the U.S. Food and Drug Administration no longer recognizes the decrease in polyp burden as a sufficient chemoprevention trial treatment endpoint requiring a measure of "clinical benefit." To develop endpoints for future industry-sponsored chemopreventive trials, the International Society for Gastrointestinal Hereditary Tumors (InSIGHT) developed an FAP staging and intervention classification scheme for lower-GI tract polyposis.

Methods

Twenty-four colonoscopy or sigmoidoscopy videos were reviewed by 26 clinicians familiar with diagnosis and treat

SUBMITTER: Lynch PM 

PROVIDER: S-EPMC5570515 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature